FBLG vs RGEN vs TMO vs ILMN

For growth investors, Repligen Corporation (RGEN) is the stronger pick with 16.

4% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). Illumina, Inc. (ILMN) offers the better valuation at 25. 5x trailing P/E (27. 2x forward), making it the more compelling value choice. Analysts rate FibroBiologics, Inc. Common Stock (FBLG) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Illumina, Inc.

(ILMN) is the cheapest at 25. 5x versus Repligen Corporation at 147. 0x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 18. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Illumina, Inc. wins at 6. 43x versus Thermo Fisher Scientific Inc. 's 8. 86x.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +2. 8%, compared to -99. 8% for FibroBiologics, Inc. Common Stock (FBLG). Over 10 years, the gap is even starker: RGEN returned +358. 2% versus FBLG's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), FibroBiologics, Inc.

Common Stock (FBLG) is the lower-risk stock at 0. 64β versus Repligen Corporation's 1. 71β — meaning RGEN is approximately 168% more volatile than FBLG relative to the S&P 500. On balance sheet safety, Repligen Corporation (RGEN) carries a lower debt/equity ratio of 33% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Repligen Corporation (RGEN) is pulling ahead at 16.

4% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -23. 5% for FibroBiologics, Inc. Common Stock. Over a 3-year CAGR, TMO leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus 0. 0% for FibroBiologics, Inc. Common Stock — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus 0. 0% for FBLG. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Illumina, Inc. (ILMN) is the more undervalued stock at a PEG of 6. 43x versus Thermo Fisher Scientific Inc. 's 8. 86x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 18. 7x forward P/E versus 61. 7x for Repligen Corporation — 43. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FBLG: 14416. 1% to $180. 00.

In this comparison, TMO (0.

4% yield) pays a dividend. FBLG, RGEN, ILMN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, FibroBiologics, Inc.

Common Stock (FBLG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 64)). Repligen Corporation (RGEN) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FBLG: -99. 8%, RGEN: +358. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FBLG is a small-cap quality compounder stock; RGEN is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock; ILMN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.